SCHEMBL2802214

SCHEMBL2802214

NS(=O)(=O)c1ccccc1S(=O)(=O)NC(=O)c1ccc(Br)c(OCCC(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 2/20 0.47
SMPD1 P17405 1/20 0.35
HDAC8 Q9BY41 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
STAT3 P40763 1/20 0.34
STAT1 P42224 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA9 Q16790 1/20 0.34
F10 P00742 2/20 0.33
PRSS1 P07477 2/20 0.33
CYSLTR2 Q9NS75 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2802125 0.90 PTGES (0.51) PTGESHDAC8MEN1NPC1ALDH1A1
SCHEMBL2802679 0.88 PTGES (0.48) PTGESSMPD1HDAC8MEN1NPC1
SCHEMBL13066214 0.87 PTGES (0.47) PTGESMEN1NPC1LMNARAB9A
SCHEMBL978913 0.86 PTGES (0.47) PTGESSMPD1
SCHEMBL2802236 0.86 PTGES (0.47) PTGESSMPD1
SCHEMBL978258 0.84 PTGES (0.52) PTGESSMPD1HDAC8NPC1MAPT
SCHEMBL2803029 0.84 PTGES (0.46) PTGESMEN1LMNAMAPTRAB9A
SCHEMBL13066063 0.84 PTGES (0.47) PTGESCA1CA2CA9F10
SCHEMBL2803047 0.84 PTGES (0.49) PTGESSMPD1HDAC8MEN1NPC1
SCHEMBL2805238 0.83 PTGES (0.48) PTGESMEN1ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
WO-2010132016-A1 BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy ASTRAZENECA AB (SE) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292279-A1 Bis-(Sulfonylamino) Derivatives in Therapy PTGER1, SULT2A1, SULT1E1 PTGES 9/4885SMPD1 971/4885HDAC8 3891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.